Company Profile
Citius Pharma Stock Price, News & Catalysts
- Ticker:
- CTXR
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.54 USD (+1.73%)
Close
Last updated: October 1, 2026
16.6M USD
Market cap
Why the stock is moving
As of Oct 1, 2026, CTXR closed up 1.73% at $0.5402. No new same-company headline was identified in the current news window.
Company overview
Critical-Care and Oncology Portfolio
Citius Pharmaceuticals develops and commercializes products for oncology, infectious disease, and other critical-care settings. The business includes a majority interest in publicly traded Citius Oncology together with wholly owned late-stage programs.
LYMPHIR in Cutaneous T-Cell Lymphoma
LYMPHIR is an FDA-approved targeted fusion protein for adults with relapsed or refractory cutaneous T-cell lymphoma after at least one prior systemic therapy. Commercialization is conducted through Citius Oncology, giving the broader group an approved oncology franchise.
Mino-Lok Catheter Salvage Therapy
Mino-Lok is an antibiotic lock solution designed to treat catheter-related bloodstream infections while preserving the indwelling central venous catheter. The product combines antimicrobial and anti-biofilm components and completed a Phase 3 study that met its primary and secondary endpoints.
Halo-Lido for Hemorrhoids
Halo-Lido is a topical formulation combining halobetasol and lidocaine for symptomatic treatment of hemorrhoids. The candidate has completed a Phase 2b study, and the company is evaluating the regulatory path for further development.
Lifecycle and Combination Development
Investigator-sponsored studies are exploring LYMPHIR in sequences or combinations with other cancer treatments, including checkpoint inhibitors and CAR-T therapy. These programs may extend the clinical role of the approved product beyond its initial label.
Portfolio-Based Structure
Citius uses separate subsidiaries and strategic transactions to finance and commercialize individual assets. This structure allows the company to retain economic exposure to LYMPHIR while independently advancing Mino-Lok and Halo-Lido.
Future catalysts
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Citius Pharma (CTXR)?
Citius Pharma (CTXR) most recently closed at 0.54 USD, a +1.73% move versus the previous session.
What is the market cap of Citius Pharma (CTXR)?
Citius Pharma currently has a market capitalization of 16.6M USD on BioPharmSignal.
What does Citius Pharma do?
Critical-Care and Oncology Portfolio Citius Pharmaceuticals develops and commercializes products for oncology, infectious disease, and other critical-care settings. The business includes a majority interest in publicly traded Citius Oncology together with wholly owned late-stage programs. LYMPHIR in Cutaneous T-Cell Lymphoma LYMPHIR is an FDA-approved...
On which exchange is CTXR stock listed?
Citius Pharma (CTXR) is associated with NASDAQ, United States, Biopharma.
What is CAR-T?
Lifecycle and Combination Development Investigator-sponsored studies are exploring LYMPHIR in sequences or combinations with other cancer treatments, including checkpoint inhibitors and CAR-T therapy.
Which conditions is Citius Pharma targeting with CAR-T?
Citius Pharma is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
What is Critical-Care?
Critical-Care and Oncology Portfolio Citius Pharmaceuticals develops and commercializes products for oncology, infectious disease, and other critical-care settings.
What is Oncology?
Critical-Care and Oncology Portfolio Citius Pharmaceuticals develops and commercializes products for oncology, infectious disease, and other critical-care settings.